metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mBC - Triple negative (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
versus carboplatin, pegylated liposomal doxorubicin and cyclophosphamide
	atezolizumab based treatment
	NSABP B-59/GBG 96-GeparDouze, 2018 Journal of Clinical Oncology NCT03281954	RCT	mBC - Triple negative (TNBC) - (neo)adjuvant (NA)	atezolizumab plus NAC (neoadjuvant chemotherapy)	placebo plus NAC	Patients with centrally-confirmed ER-neg, PR-neg, HER2-neg invasive breast cancer by ASCO/CAP guidelines, stage T2 or T3 if cN0 or cN1 with negative biopsy or T1c, T2, or T3 if cN1 with positive biopsy or cN2 or cN3. LVEF > 55% and no significant cardiac history	773 / 777	NA	inconclusive	inconclusive 20 % decrease in events or deaths (EFS) (PE)
la/mBC - TNBC - L1 - all population breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1) la/mBC - TNBC - L1 - all population
versus nab-paclitaxel
	atezolizumab plus nab-paclitaxel
	IMpassion-130 (all population), 2018 Lancet Oncol. 2020; 21:44-59 N. Engl. J. Med. 2018; 379:2108-2121 Jpn. J. Clin. Oncol. 2019; 49:1083-1091 Ann. Oncol. 2020; : Ann Oncol 2021 Aug;32(8):983-993. NCT02425891	RCT	la/mBC - TNBC - L1 - all population	atezolizumab plus nab-paclitaxel	placebo plus nab-paclitaxel	patients with untreated metastatic triple-negative breast cancer (TNBC) treated with nab-paclitaxel	451 / 451	low	conclusif	inconclusive 14 % decrease in deaths (OS) (PE) demonstrated 20 % decrease in progression or deaths (PFS) (PE) suggested 20 % decrease in PFS (extension)
versus paclitaxel
	atezolizumab plus paclitaxel
	IMpassion-131 (all population), 2020 Ann Oncol 2021; 32:994-1004-. NCT03125902	RCT	la/mBC - TNBC - L1 - all population	Atezolizumab plus paclitaxel	placebo plus paclitaxel	Patients had metastatic or unresectable locally advanced measurable TNBC, had received no prior chemotherapy or targeted therapy for aTNBC and had completed any prior (neo)adjuvant chemotherapy for early breast cancer 12 months before being randomised to the trial.	431 / 220	low	inconclusive	inconclusive 14 % decrease in progression or deaths (PFS) (PE) Atezolizumab (Tecentriq) in combination with paclitaxel did not demonstrate a statistically significant improvement in progression-free survival (PFS) as a first-line treatment for patients with PD-L1–positive triple-negative breast cancer (TNBC) / qualitative results only NO ROB
la/mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1) la/mBC - TNBC - L1 - PDL1 positive
versus nab-paclitaxel
	atezolizumab plus nab-paclitaxel
	IMpassion-130 (PDL1>1%), 2018 Lancet Oncol. 2020; 21:44-59 N. Engl. J. Med. 2018; 379:2108-2121 Jpn. J. Clin. Oncol. 2019; 49:1083-1091 Ann. Oncol. 2020; : Ann Oncol 2021 Aug;32(8):983-993. NCT02425891	RCT	la/mBC - TNBC - L1 - PDL1 positive	atezolizumab plus nab-paclitaxel	placebo plus nab-paclitaxel	patients with untreated metastatic triple-negative breast cancer treated with nab-paclitaxel, and PDL1 positive population (>1%)	185 / 184	low	conclusif	suggested 29 % decrease in deaths (OS) (PE) demonstrated 38 % decrease in progression or deaths (PFS) (PE) suggested 37 % decrease in PFS (extension)
versus paclitaxel
	atezolizumab plus paclitaxel
	IMpassion-131 (PD-L1 > 1%), 2020 Ann Oncol 2021; 32:994-1004-. NCT03125902	RCT	la/mBC - TNBC - L1 - PDL1 positive	Atezolizumab plus paclitaxel	placebo plus paclitaxel	Patients had metastatic or unresectable locally advanced measurable TNBC, had received no prior chemotherapy or targeted therapy for aTNBC and had completed any prior (neo)adjuvant chemotherapy for early breast cancer 12 months before being randomised to the trial.	191 / 101	low	inconclusive	inconclusive 18 % decrease in progression or deaths (PFS) (PE)
la/mBC - TNBC - L2 - all population breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - all population
versus carboplatin, gemcitabine
	atezolizumab based treatment
	IMpassion-132 (ITT population), 2024 Future Oncol 2019; 15:1951-1961 Ann Oncol 2024; 35:630-642-. NCT03371017	RCT	la/mBC - TNBC - L2 - all population	atezolizumab plus SOC	placebo plus SOC	Patients with locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy or surgery in early stage	297 / 298	low	inconclusive	no statistically significant result OS was not improved by adding atezolizumab to chemotherapy for rapidly relapsing PD-L1-positive TNBC
versus carboplatin
	atezolizumab based treatment
	TBCRC, 2024 NCT03206203	RCT	la/mBC - TNBC - L2 - all population	carboplatin atezolizumab, 1200 mg	carboplatin	clinical stage IV or metastatic invasive TN breast cancer. 0 to 1 prior treatments for metastatic disease, and no prior carboplatin in the metastatic setting or prior immune-oncology treatment were eligible. Patients were not stratified by PD-L1 status.	56 / 50	high	inconclusive	suggested 54 % decrease in deaths (OS) inconclusive 34 % decrease in progression or deaths (PFS) (PE)
versus pegylated liposomal doxorubicin and cyclophosphamide
	atezolizumab based treatment
	Alice, 2022 J Transl Med 2020; 18:252-. Nat Med 2022; 28:2573-2583-. NCT03164993	RCT	la/mBC - TNBC - L2 - all population	atezolizumab and pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide	placebo and pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide	patients with mTNBC, 18 years of age or older, with no more than one prior line of chemotherapy in the metastatic setting. Inclusion of patients both with and without PD-L1 expression in tumors was allowed in this trial	42 / 28	high	suggested	suggested 43 % decrease in progression or deaths (PFS) (PE) The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit
la/mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - PDL1 positive
versus carboplatin, gemcitabine
	atezolizumab based treatment
	IMpassion-132 (PD-L1 positive population), 2024 Future Oncol 2019; 15:1951-1961 Ann Oncol 2024; 35:630-642-. NCT03371017	RCT	la/mBC - TNBC - L2 - PDL1 positive	atezolizumab plus SOC	placebo plus SOC	Patients with locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy or surgery in early stage	177 / 177	low	inconclusive	inconclusive 7 % decrease in deaths (OS) (PE)

mBC - Triple negative (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - (neo)adjuvant (NA)

la/mBC - TNBC - L1 - all population breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1) la/mBC - TNBC - L1 - all population

la/mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1) la/mBC - TNBC - L1 - PDL1 positive

la/mBC - TNBC - L2 - all population breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - all population

la/mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - PDL1 positive